Skip to content

Ionis Pharmaceuticals

US · IONS #1749 by market cap Listed 1970
26.58 -0.64 -2.35%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Recent news

  • Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $70
    Market Newswire · 2026/11/12
  • Rating change
    Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $87
    Market Newswire · 2026/10/21
  • Rating change
    RBC Capital Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85
    Market Newswire · 2026/10/9
  • Company notice
    Iondrive Ltd: Large-Scale Trials Validate Scalability of ION's Technology
    N/A · 2024/7/30
  • A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $53 to $85
    Market Newswire · 2026/11/11
  • Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q3 Loss $0.66 a Share, Vs. FactSet Est of $1.23 Loss
    MT Newswires · 2026/11/9
  • Rating change
    Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $85
    Market Newswire · 2026/9/25
  • A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $41 to $100
    Market Newswire · 2026/11/10
  • Company notice
    Liberta: Announcement that Family Service Eiko Co., Ltd. will hold a press conference for the first time in Tokyo to remove heavy metal ions, PFOS, and PFOA removal water server “swee,” which was jointly developed by Family Service Eiko Co., Ltd. with Shinshu University
    JPX · 2025/4/11
  • Rating change
    BMO Capital Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $54
    Market Newswire · 2026/9/24
  • Rating change
    H.C. Wainwright Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/10/26
  • Rating change
    UBS Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $88
    Market Newswire · 2026/10/16
  • Rating change
    Citi Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/10/29
  • Rating change
    Raymond James Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $79
    Market Newswire · 2026/10/20
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Maze Therapeutics, Inc. (MAZE) and Abbott Laboratories (ABT)
    TipRanks · 2026/10/21
  • Rating change
    CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85
    Market Newswire · 2026/10/30
  • Rating change
    UBS Initiates Ionis Pharmaceuticals(IONS.US) With Buy Rating, Announces Target Price $88
    Market Newswire · 2026/10/15
  • Company notice
    Cacco: Ion's online market, "Green Beans", has adopted "O-PLUX" as a measure against credit card fraud.
    JPX · 2024/6/6
  • Rating change
    BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $91
    Market Newswire · 2026/10/9
  • A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $66 to $104
    Market Newswire · 2026/10/22
  • Rating change
    A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $70 to $100
    Market Newswire · 2026/9/23
  • Rating change
    A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $84 to $100
    Market Newswire · 2026/9/24
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE) and Ionis Pharmaceuticals (IONS)
    TipRanks · 2026/9/23
  • Rating change
    J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $70
    Market Newswire · 2026/9/22
  • Rating change
    Goldman Sachs Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $56
    Market Newswire · 2026/9/14

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:59:29 · For reference only, not investment advice and not tailored to your situation.

Ionis Pharmaceuticals discussion 0 comments

Add a comment